Epilepsy and Depression

Across epidemiologic, clinical, and mechanistic studies, epilepsy and depression exhibit a robust, bidirectional connection. Depression is present in roughly one in four people with epilepsy and is a major driver of poor quality of life and suicidality. Longitudinal data indicate that individuals with a history of depression face elevated risk of later epilepsy, suggesting common vulnerability pathways beyond the psychosocial effects of seizures. Shared biology includes limbic network dysfunction (notably hippocampal/temporal circuits), monoaminergic imbalance, HPA axis dysregulation, and neuroinflammation. Clinically, these links inform screening and treatment: validated tools like the NDDI-E or PHQ-9 should be used routinely, and any positive screen or suicidality warrants prompt intervention. ASM selection should account for psychiatric profiles: lamotrigine often benefits mood, while levetiracetam, topiramate, phenobarbital, and perampanel can worsen mood or irritability in some patients. Antidepressants are effective; SSRIs/SNRIs and mirtazapine are generally safe at therapeutic doses, while bupropion and certain tricyclics carry higher seizure risk. Coordination is key because enzyme-inducing ASMs (carbamazepine, phenytoin, phenobarbital, primidone) can lower antidepressant exposure, and some SSRIs inhibit CYP enzymes affecting ASM levels. Nonpharmacologic therapies—CBT/behavioral activation, exercise, sleep optimization—improve depressive symptoms and support seizure control. Vagus nerve stimulation stands out for dual efficacy in refractory epilepsy and treatment-resistant depression. Systematic, integrated care that prioritizes mood as a core epilepsy outcome improves safety, adherence, and overall prognosis.

Traditional East Asian medicine conceptualizes both epilepsy (dian xian) and depression (yu zheng) through shared patterns—often Liver qi stagnation with phlegm obstructing the orifices and disharmony of Heart–Spleen—leading to disrupted shen (mind–spirit). Treatment aims to course the Liver, transform phlegm, and calm the shen, typically with acupuncture and individualized herbal formulas. Contemporary evidence supports acupuncture’s potential to relieve depressive symptoms (especially versus usual care), while effects versus sham are mixed; for epilepsy, clinical trials are few and heterogeneous, with inconclusive impact on seizure frequency. Given limited certainty, these modalities are best positioned as adjuncts to guideline-based neurological and psychiatric care. Practical integration may include acupuncture focused on stress regulation and sleep (e.g., LR3, PC6, HT7, DU20, ST36/ST40) alongside breathwork, qigong, or tai chi to reduce arousal and improve sleep quality—common precipitants of seizures and contributors to low mood. Any herbal therapy should be coordinated with the treating neurologist because of potential interactions with ASMs (for example, additive sedation, effects on CYP enzymes, or electrolyte changes that could affect seizure threshold). When framed within a collaborative care model that respects both biomedical safety and patient preferences, eastern modalities can complement core treatments by addressing stress, sleep, and resilience, while neurologic management controls seizures and psychiatric care treats depressive symptoms.